AngioDynamics, Inc.

As of January 5, 2024, AngioDynamics, Inc. is considered overvalued with a risky outlook due to negative return metrics and high valuation ratios, despite a recent 1-year return of 44.87% that outperformed the S&P 500.

As of January 5, 2024, AngioDynamics, Inc. is considered overvalued with a risky valuation grade, highlighted by a Price to Book Value of 2.44, an EV to EBITDA of 410.27, a negative P/E ratio of -21.90, and a three-year return of -50.42%, significantly underperforming the S&P 500's 58.74% return.

As of June 3, 2025, AngioDynamics, Inc. exhibits a bullish technical trend, supported by positive indicators such as the weekly MACD, daily moving averages, and KST across multiple time frames.

As of March 2022, the management team of AngioDynamics, Inc. includes Mr. Howard Donnelly (Independent Chairman), Mr. James Clemmer (President and CEO), and several independent directors: Ms. Eileen Auen, Mr. Wesley Johnson, Ms. Karen Licitra, Mr. Dennis Meteny, and Ms. Jan Reed. This team oversees the company's governance and strategic direction.

AngioDynamics, Inc. designs and manufactures medical devices for vascular access, peripheral vascular disease treatment, and oncology. As of February 2025, it reported net sales of $72 million and a net loss of $4 million, with a market cap of $416.33 million.

As of Jun 18, AngioDynamics, Inc. has a market capitalization of 416.33 million, with net sales of 283.31 million and a net profit of -41.40 million over the last four quarters. Shareholder's funds are 205.59 million, and total assets are 317.67 million.